A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

By sjmartinez • June 22, 2024

McKetin R, Degan TJ, Saunders L, Nguyen L, Dore G, Shoptaw S, Farrell M, Degenhardt L, Kelly PJ, Turner A, Clare PJ, Dean OM, Arunogiri S, Colledge-Frisby S, Koeijers J, Goodman-Meza D, Sinclair B, Reid D, Hill H, Hayllar J, Christmass M, Cordaro F, Lundin R, Liaw W, Liu D, Holyoak E, Wu BT, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Byrne M, Russell S, Zahra E, Berk M. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. Trials. 2024 Jun 22;25(1):408. doi: 10.1186/s13063-024-08238-y. PMID: 38907288; PMCID: PMC11193254.

Tags: Addiction, Clinical Trial, depression, Infectious Diseases, Methamphetamine, Mirtazapine, pharmacotherapy, Psychiatry, Publications, sleep, substance use disorders, Treatment

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin[...]

Mirtazapine reduces hypothetical methamphetamine demand in humans

Rush CR, Santos GM, McMahan VM, Fraser A, Clark J, Luna Marti X, Walker JE, Shoptaw S, Coffin PO. Mirtazapine reduces hypothetical methamphetamine demand in[...]

A systematic nomenclature for mpox viruses causing outbreaks with sustained human-to-human transmission

Ruis C, Lusamaki E, O'Toole A, Otieno JR, Colquhoun R, Roemer C, Wawina-Bokalanga T, Tshiani-Mbaya O, Jansen D, Makangara JC, Agrawal A, Abu-Raddad LJ, Ahuka-Mundeke[...]